PL3071192T3 - Związek kurkufenol do zastosowania w leczeniu nowotworu - Google Patents

Związek kurkufenol do zastosowania w leczeniu nowotworu

Info

Publication number
PL3071192T3
PL3071192T3 PL14815145T PL14815145T PL3071192T3 PL 3071192 T3 PL3071192 T3 PL 3071192T3 PL 14815145 T PL14815145 T PL 14815145T PL 14815145 T PL14815145 T PL 14815145T PL 3071192 T3 PL3071192 T3 PL 3071192T3
Authority
PL
Poland
Prior art keywords
treating cancer
curcuphenol compound
curcuphenol
compound
cancer
Prior art date
Application number
PL14815145T
Other languages
English (en)
Inventor
Wilfred A. Jefferies
Reinhard Gabathuler
Raymond Andersen
David Williams
Lilian NOHARA
Original Assignee
Cava Healthcare Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cava Healthcare Inc. filed Critical Cava Healthcare Inc.
Publication of PL3071192T3 publication Critical patent/PL3071192T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL14815145T 2013-11-20 2014-11-20 Związek kurkufenol do zastosowania w leczeniu nowotworu PL3071192T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906817P 2013-11-20 2013-11-20
EP14815145.9A EP3071192B1 (en) 2013-11-20 2014-11-20 Curcuphenol compound for use in treating cancer
PCT/US2014/066543 WO2015077411A1 (en) 2013-11-20 2014-11-20 Curcuphenol compounds for increasing mhc-i expression

Publications (1)

Publication Number Publication Date
PL3071192T3 true PL3071192T3 (pl) 2020-06-29

Family

ID=52117996

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14815145T PL3071192T3 (pl) 2013-11-20 2014-11-20 Związek kurkufenol do zastosowania w leczeniu nowotworu

Country Status (10)

Country Link
US (4) US20150147314A1 (pl)
EP (2) EP3071192B1 (pl)
JP (4) JP6560215B2 (pl)
CN (1) CN106456572A (pl)
CA (1) CA2930156C (pl)
DK (1) DK3071192T3 (pl)
ES (1) ES2775577T3 (pl)
HU (1) HUE049301T2 (pl)
PL (1) PL3071192T3 (pl)
WO (1) WO2015077411A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150147314A1 (en) 2013-11-20 2015-05-28 Biommune Technologies Inc. Curcuphenol compounds for increasing mhc-i expression
WO2017015615A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
ES3047409T3 (en) * 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
CN113906006A (zh) * 2019-01-31 2022-01-07 卡瓦医疗保健公司 用于增加mhc-i表达和调节组蛋白去乙酰化酶活性的化合物
TW202214245A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 雙非癌藥物用於製備治療癌症之醫藥組合物的用途
CN116583295A (zh) * 2020-12-07 2023-08-11 印地安纳大学理事会 使用白术内酯i使癌细胞对免疫攻击敏感的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261939A (ja) * 1985-09-10 1987-03-18 Yamanouchi Pharmaceut Co Ltd クルクフエノ−ル誘導体及びこれを含有する医薬
KR100439425B1 (ko) * 2001-03-22 2004-07-05 (주)바이오케어 잔토리졸을 포함하는 조성물 및 그 용도
KR100571159B1 (ko) * 2003-06-24 2006-04-18 박광균 항암제로 유발되는 독성의 억제제 및 이를 함유하는항암제 조성물
CA2688570A1 (en) * 2007-05-31 2008-12-04 F.P.L. Pharma Inc. Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
US20150147314A1 (en) 2013-11-20 2015-05-28 Biommune Technologies Inc. Curcuphenol compounds for increasing mhc-i expression

Also Published As

Publication number Publication date
EP3639815A1 (en) 2020-04-22
EP3071192A1 (en) 2016-09-28
DK3071192T3 (da) 2020-03-16
US20150147314A1 (en) 2015-05-28
EP3071192B1 (en) 2019-12-18
JP2022093724A (ja) 2022-06-23
JP7071570B2 (ja) 2022-05-19
US12011421B2 (en) 2024-06-18
JP2019196380A (ja) 2019-11-14
US10751296B2 (en) 2020-08-25
JP6560215B2 (ja) 2019-08-14
JP2021100982A (ja) 2021-07-08
ES2775577T3 (es) 2020-07-27
US20170319508A1 (en) 2017-11-09
WO2015077411A1 (en) 2015-05-28
JP2016539129A (ja) 2016-12-15
US11197832B2 (en) 2021-12-14
HUE049301T2 (hu) 2020-09-28
CA2930156C (en) 2023-11-07
CA2930156A1 (en) 2015-05-28
US20200375917A1 (en) 2020-12-03
CN106456572A (zh) 2017-02-22
US20220062195A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
IL274462B (en) Anti-b7–h1 antibodies for the treatment of tumors
IL245731A0 (en) Combined treatment for cancer
IL245281A0 (en) Methods and preparations for the treatment of cancer
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
SG11201603050TA (en) Methods for treating cancers
ZA201603332B (en) Gla monotherapy for use in cancer treatment
GB201322725D0 (en) Cancer therapy
IL244353A0 (en) Compounds and use for cancer treatment
SG11201509707QA (en) Cancer therapy
SG11201507847UA (en) Cancer therapy
ZA201505937B (en) Caix stratification based cancer treatment
PL2968226T3 (pl) Kompozycje oksprenololu do leczenia raka
IL245037A0 (en) Treatment for pancreatic cancer
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
HUE048625T2 (hu) Módszer rák kezelésére
EP2915800A4 (en) INGENOL DERIVATIVES USEFUL IN THE TREATMENT OF CANCER
EP2961412A4 (en) CANCER THERAPY
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201300546D0 (en) Cancer Treatment
GB201321531D0 (en) Treatment for cancers
GB201322764D0 (en) Treating places
GB201317213D0 (en) Cancer Therapy
GB201322958D0 (en) Uses of oligouronates in cancer treatment
AU2013904506A0 (en) Compounds for treating cancer